^
HRD
Pancreatic Cancer
ABT-888
Resistant: C4 – Case Studies
Clin Cancer Res - 3 weeks
BRCA2 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
BRCA1 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
Pancreatic Adenocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: A1 - Approval
No biomarker
Pancreatic Adenocarcinoma
5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan
Sensitive: A1 - Approval
No biomarker
Pancreatic Cancer
erlotinib
Sensitive: A1 - Approval
No biomarker
Pancreatic Cancer
GEM-CAP
Sensitive: A2 - Guideline
No biomarker
Pancreatic Adenocarcinoma
LV5FU2
Sensitive: A2 - Guideline
No biomarker
Pancreatic Adenocarcinoma
CAPOX
Sensitive: A2 - Guideline
NTRK3 fusion
Pancreatic Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Pancreatic Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
No biomarker
Pancreatic Cancer
5-fluorouracil + nanoliposomal irinotecan
Sensitive: A2 - Guideline
No biomarker
Pancreatic Cancer
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
No biomarker
Pancreatic Cancer
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Pancreatic Cancer
5-fluorouracil + irinotecan
Sensitive: A2 - Guideline
NTRK3 fusion
Pancreatic Adenocarcinoma
entrectinib
Sensitive: A2 - Guideline
No biomarker
Pancreatic Cancer
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Pancreatic Adenocarcinoma
erlotinib
Sensitive: A2 - Guideline
No biomarker
Pancreatic Adenocarcinoma
capecitabine
Sensitive: A2 - Guideline
No biomarker
Pancreatic Adenocarcinoma
5-fluorouracil + capecitabine
Sensitive: A2 - Guideline
No biomarker
Pancreatic Adenocarcinoma
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Pancreatic Adenocarcinoma
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Pancreatic Adenocarcinoma
gemcitabine + capecitabine
Sensitive: A2 - Guideline
BRCA1 mutation
Pancreatic Adenocarcinoma
cisplatin + gemcitabine
Sensitive: A2 - Guideline
BRCA2 mutation
Pancreatic Adenocarcinoma
cisplatin + gemcitabine
Sensitive: A2 - Guideline
PALB2 mutation
Pancreatic Adenocarcinoma
cisplatin + gemcitabine
Sensitive: A2 - Guideline
No biomarker
Pancreatic Cancer
FOLFIRINOX
Sensitive: A2 - Guideline
No biomarker
Pancreatic Cancer
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
NTRK3 fusion
Pancreatic Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Pancreatic Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Pancreatic Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Pancreatic Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Pancreatic Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Pancreatic Cancer
larotrectinib
Sensitive: A2 - Guideline
No biomarker
Pancreatic Adenocarcinoma
5-fluorouracil + irinotecan
Sensitive: A2 - Guideline
NTRK1 fusion
Pancreatic Adenocarcinoma
entrectinib
Sensitive: A2 - Guideline
MSI-H/dMMR
Pancreatic Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
NTRK2 fusion
Pancreatic Adenocarcinoma
entrectinib
Sensitive: A2 - Guideline
No biomarker
Pancreatic Cancer
FG-3019
Sensitive: B - Late Trials
No biomarker
Pancreatic Cancer
capecitabine
Sensitive: B - Late Trials
No biomarker
Pancreatic Cancer
devimistat
Sensitive: B - Late Trials
TMB-H
Pancreatic Cancer
pembrolizumab
Sensitive: B - Late Trials
No biomarker
Pancreatic Ductal Adenocarcinoma
SBP-101
Sensitive: B - Late Trials
TMB-H
Pancreatic Cancer
PD1 inhibitor
Sensitive: B - Late Trials
ELAVL1 expression
Pancreatic Cancer
NUC-3373
Sensitive: B - Late Trials
No biomarker
Pancreatic Ductal Adenocarcinoma
gemcitabine
Sensitive: B - Late Trials
No biomarker
Pancreatic Ductal Adenocarcinoma
gemcitabine + capecitabine
Sensitive: B - Late Trials
No biomarker
Pancreatic Cancer
FOLFIRINOX + GEM-CAP
Sensitive: B - Late Trials
No biomarker
Pancreatic Cancer
TH 302
Sensitive: B - Late Trials
CCL11 overexpression
Pancreatic Ductal Adenocarcinoma
tertomotide
Sensitive: B - Late Trials
No biomarker
Pancreatic Cancer
CORT125134
Sensitive: B - Late Trials
No biomarker
Pancreatic Ductal Adenocarcinoma
CEND-1
Sensitive: B - Late Trials
RET fusion
Pancreatic Cancer
pralsetinib
Sensitive: C1 - Off-label
BRCA2 mutation
Pancreatic Cancer
rucaparib
Sensitive: C1 - Off-label
NTRK1 fusion
Pancreatic Adenocarcinoma
larotrectinib
Sensitive: C1 - Off-label
BRCA1 mutation
Pancreatic Cancer
rucaparib
Sensitive: C1 - Off-label
KRAS G12C
Pancreatic Cancer
sotorasib
Sensitive: C1 - Off-label
BRAF V600E
Pancreatic Cancer
encorafenib + binimetinib
Sensitive: C1 - Off-label
PD-L1 expression
Pancreatic Cancer
pembrolizumab
Sensitive: C1 - Off-label
BRAF V600E
Pancreatic Cancer
vemurafenib
Sensitive: C1 - Off-label
HER-2 overexpression
Pancreatic Cancer
trastuzumab
Sensitive: C1 - Off-label
BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
olaparib
Sensitive: C1 - Off-label
ATM mutation
Pancreatic Cancer
olaparib
Sensitive: C1 - Off-label
ATM mutation
Pancreatic Ductal Adenocarcinoma
olaparib
Sensitive: C1 - Off-label
RET fusion
Pancreatic Adenocarcinoma
pralsetinib
Sensitive: C1 - Off-label
TMB-H
Pancreatic Adenocarcinoma
pembrolizumab
Sensitive: C1 - Off-label
RET fusion
Pancreatic Cancer
selpercatinib
Sensitive: C1 - Off-label
BRCA1 mutation
Pancreatic Ductal Adenocarcinoma
olaparib
Sensitive: C1 - Off-label
BRCA2 mutation
Pancreatic Cancer
ABT-888
Sensitive: C2 – Inclusion Criteria
PALB2 mutation
Pancreatic Cancer
ABT-888
Sensitive: C2 – Inclusion Criteria
BRCA1 mutation
Pancreatic Cancer
ABT-888
Sensitive: C2 – Inclusion Criteria
PALB2 mutation
Pancreatic Cancer
rucaparib
Sensitive: C2 – Inclusion Criteria
NRAS mutation
Pancreatic Cancer
avelumab
Sensitive: C2 – Inclusion Criteria
KRAS mutation
Pancreatic Cancer
avelumab
Sensitive: C2 – Inclusion Criteria
NRG1 fusion
Pancreatic Cancer
MCLA-128
Sensitive: C2 – Inclusion Criteria
KRAS mutation
Pancreatic Ductal Adenocarcinoma
pembrolizumab + trametinib
Sensitive: C2 – Inclusion Criteria
TP53 mutation
Pancreatic Cancer
gemcitabine + albumin-bound paclitaxel
Sensitive: C3 – Early Trials
HGF-H
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Resistant: C3 – Early Trials
MSI-L/dMMR
Pancreatic Ductal Adenocarcinoma
nivolumab
Sensitive: C3 – Early Trials
MSI-L/dMMR
Pancreatic Ductal Adenocarcinoma
ipilimumab
Sensitive: C3 – Early Trials
MSI-L/dMMR
Pancreatic Ductal Adenocarcinoma
pembrolizumab
Sensitive: C3 – Early Trials
KRAS G12R
Pancreatic Adenocarcinoma
selumetinib
Sensitive: C3 – Early Trials
UGT1A1*28 + UGT1A1*6
Pancreatic Cancer
FOLFIRINOX
Sensitive: C3 – Early Trials
KRAS exon 2 mutation
Pancreatic Cancer
erlotinib
Resistant: C3 – Early Trials
EPHB4 expression
Pancreatic Cancer
gemcitabine + albumin-bound paclitaxel
Sensitive: C3 – Early Trials
KRAS G12R
Pancreatic Cancer
cobimetinib
Sensitive: C3 – Early Trials
KRAS mutation
Pancreatic Adenocarcinoma
trametinib
Sensitive: C3 – Early Trials
PALB2 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
BRCA1 mutation + BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
FANCF mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
MSH2 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
BRCA1 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials